Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2500${count})

  • Alpha-Synuclein Imaging, 2020
    Alpha-Synuclein PET Tracer Discovery
    Ken Griffin Alpha-synuclein Imaging Competition Logo

    Study Rationale:
    The discovery of new treatments for Parkinson’s disease has been slowed by the time it takes to answer the question “did a drug work” in a clinical trial. Tests that can assess...

  • Therapeutic Pipeline Program, 2020
    Phase II Trial of Bone Marrow-Derived Mesenchymal Stem Cells as a Disease-Modifying Therapy for Parkinson’s Disease

    Study Rationale: 
    Chronic brain inflammation plays a critical role in the development and progression of Parkinson’s disease. This inflammation damages the brain, disrupts the blood-brain barrier, and...

  • Target Advancement Program, 2020
    Gene Therapy Approach to Reduce Alpha‐synuclein Aggregation in a Model of Parkinson's

    Study Rationale:
    A hallmark of Parkinson’s disease is the accumulation of an abnormal form of the protein alpha-synuclein inside brain cells. The team plans to use a gene therapy approach to insert a...

  • Improved Biomarkers and Clinical Outcome Measures, 2020
    Development of a Non-Invasive Ophthalmic Diagnostic for Parkinson’s Disease

    Study Rationale:
    Currently, diagnosis of Parkinson’s disease relies on extensive neurological and physical examinations. A hallmark of Parkinson's is misfolded alpha-synuclein that forms aggregates...

  • Therapeutic Pipeline Program, 2020
    Pre-clinical Development of Compounds that Modulate Mitophagy through Regulation of the Mitochondrial GTPase Miro1

    Study Rationale:
    Evidence indicates that mitochondrial dysfunction is a significant contributor to Parkinson’s disease, with the majority of patients exhibiting a shared defect in the processing of...

  • Therapeutic Pipeline Program, 2020
    Pregnenolone for the Treatment of L-DOPA-induced Dyskinesia in Parkinson's disease

    Study Rationale:
    Neurosteroids are substances that occur naturally in the brain and help regulate and modulate the activity of brain cells. In previous studies, the investigators demonstrated that...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.